A NOVEL, SYNTHETIC ANTIINFECTIVE DRUG CANDIDATE, R-327, FOR THE ACUTE TREATMENT OF BURN WOUNDS AND DOWNSTREAM SEQUELAE

$2,000,000FY2024Defense Health AgencyDOD

Recce Pharmaceuticals Ltd

Investigators